In the past week or so, a gold and silver miner, a struggling offshore driller, and a biotech saw some huge insider buying.

Alector Inc. cuts its workforce by nearly 50% following the failure of its dementia drug trial, signalling challenges in the ...

Join us as we dissect Summit Therapeutics' potential in the biotech sector. Can their promising drug Ansuvimab overcome the ...

Laramie startups are turning University of Wyoming research into products like natural mouthwash and kidney stone supplements ...

The Indian Institute of Integrative Medicine is launching the BioNEST Incubator at the Industrial Biotech Park, Kathua, supported by BIRAC. The incubator will nurture bioinnovation and ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

The aim of Greenford is to offer holistic branding and communications support for early-stage healthcare companies.

Biogen will pay a Chicago biotech $70 million upfront, plus up to $990 million in milestone payments, for an early-stage ...

Remix Therapeutics said it received positive preliminary results for the ongoing Phase 1 of its lead drug, REM-422, in ...

The Food and Drug Administration yesterday delivered a split decision on GSK’s blood cancer drug Blenrep, approving its use ...

The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 ...